med seneste ændringer pr. 24. april 2008

April 30, 2008 11:23 ET | Source: ALK Abello ALK Abello

Vedtægter for ALK-Abelló A/S med seneste ændringer pr. 24. april 2008

Attachments

alk-abello-vedtgter - 24-04-08.pdf

alk-abello-vedtgter - 24-04-08.pdf...

Recommended Reading

April 20, 2026 08:33 ET | Source: ALK Abello

ALK announces successful outcome of phase 2 trial with its tablet for treatment of peanut allergy demonstrating early onset of efficacy

Inside Information The ALLIANCE phase 2 trial demonstrated proof-of-concept after only 6 months of maintenance treatment in a broad patient population comprising both children and adults.Clear...
Read More
April 15, 2026 06:07 ET | Source: ALK Abello

neffy® approved as the first needle-free anaphylaxis treatment of adults and children in Canada

ALK (ALKB:DC / Nasdaq Copenhagen: ALK B) today announced that Health Canada has approved neffy® 2 mg for the emergency treatment of allergic reactions (anaphylaxis) due to insect stings or bites,...
Read More